(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 35.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Tg Therapeutics's revenue in 2025 is $386,386,000.On average, 3 Wall Street analysts forecast TGTX's revenue for 2025 to be $93,808,827,038, with the lowest TGTX revenue forecast at $91,206,355,732, and the highest TGTX revenue forecast at $97,348,588,075. On average, 4 Wall Street analysts forecast TGTX's revenue for 2026 to be $120,977,687,633, with the lowest TGTX revenue forecast at $109,953,737,934, and the highest TGTX revenue forecast at $141,895,251,177.
In 2027, TGTX is forecast to generate $153,274,812,157 in revenue, with the lowest revenue forecast at $130,179,129,520 and the highest revenue forecast at $182,393,660,860.